{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-015632","form_type":"8-K","ticker":null,"cik":"0000830656","company_name":"PRESSURE BIOSCIENCES INC","filed_at":"2023-05-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:42.382995+00:00","generated_at":"2026-06-15T18:49:06.660504+00:00","sec_items":["5.03","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Pressure BioSciences creates two new convertible preferred series with forced conversion and voting features","bullets":["Series BB: 1,000 shares, 10,000 votes per share, convertible to 10,000 common shares each.","Series CC: 2,000 shares, 8% annual dividend on $25,000 liquidation preference per share.","Series CC converts at $2.50/share; forced conversion if VWAP >= 300% of $2.50 for 10/15 trading days or exchange listing.","Both series have a 4.99% conversion restriction on beneficial ownership (waivable with 61 days' notice).","Series BB ranks junior to AA/CC; Series CC ranks pari passu with AA and senior to common stock."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-015632","json":"https://secwatch.observer/filing/0001493152-23-015632.json","markdown":"https://secwatch.observer/filing/0001493152-23-015632.md","text":"https://secwatch.observer/filing/0001493152-23-015632.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/830656/000149315223015632/0001493152-23-015632-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/830656/000149315223015632/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T18:49:06.660504+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"583d63f6e743c092842a27cfa54507989c9b3f2d","claim":"PRESSURE BIOSCIENCES INC: Filed Articles of Amendment to Restated Articles of Organization to designate Series BB Convertible Preferred Stock and Series CC Convertible Preferred Stock (effective 2023-05-01).","evidence_excerpt":"On May 1, 2023, Pressure BioSciences, Inc. (the “Company”) filed Articles of Amendment to Restated Articles of Organization (the “Amendment”) with the Secretary of the Commonwealth of Massachusetts to designate 1,000 shares of its Preferred Stock as Series BB Convertible Preferred Stock, par value $0.01 per share (the “Series BB Preferred Stock”) and 2,000 shares of Preferred Stock as Series CC Convertible Preferred Stock, par value $0.01 per share (the “Series CC Preferred Stock”).","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/830656/000149315223015632/0001493152-23-015632-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2023-05-01"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}